Switch to Ritonavir-Boosted versus Unboosted Atazanavir plus Raltegravir Dual-Drug Therapy Leads to Similar Efficacy and Safety Outcomes in Clinical Practice.

by Pierre Gantner, Firouze Bani-Sadr, Rodolphe Garraffo, Pierre-Marie Roger, Michèle Treger, Thomas Jovelin, Pascal Pugliese, David Rey, Dat’AIDS cohort
Published 2016-01-01

COPD in HIV-Infected Patients: CD4 Cell Count Highly Correlated.

by Karine Risso, Francine Guillouet-de-Salvador, Laure Valerio, Pascal Puglièse, Alissa Naqvi, Jacques Durant, Elisa Demonchy, Isabelle Perbost, Eric Cua, Charles-Hugo Marquette, Pierre-Marie Roger
Published 2017-01-01

Derivation and internal validation of a mortality risk index for aged people living with HIV: The Dat'AIDS score.

by Maxime Hentzien, Cyrille Delpierre, Pascal Pugliese, Clotilde Allavena, Christine Jacomet, Marc-Antoine Valantin, André Cabié, Lise Cuzin, David Rey, Firouzé Bani-Sadr, Moustapha Dramé, Dat’Aids Study Group
Published 2018-01-01

Antiretroviral therapy as a risk factor for chronic kidney disease: Results from traditional regression modeling and causal approach in a large observational study.

by Lise Cuzin, Pascal Pugliese, Clotilde Allavena, David Rey, Catherine Chirouze, Firouzé Bani-Sadr, André Cabié, Thomas Huleux, Isabelle Poizot-Martin, Laurent Cotte, Corinne Isnard Bagnis, Philippe Flandre, Dat’AIDS study group
Published 2017-01-01

Effectiveness and tolerance of single tablet versus once daily multiple tablet regimens as first-line antiretroviral therapy - Results from a large french multicenter cohort study.

by Laurent Cotte, Tristan Ferry, Pascal Pugliese, Marc-Antoine Valantin, Clotilde Allavena, André Cabié, Isabelle Poizot-Martin, David Rey, Claudine Duvivier, Antoine Cheret, Pierre Dellamonica, Pierre Pradat, Jean-Jacques Parienti, Dat’AIDS study group
Published 2017-01-01

Potential for Drug-Drug Interactions between Antiretrovirals and HCV Direct Acting Antivirals in a Large Cohort of HIV/HCV Coinfected Patients.

by Isabelle Poizot-Martin, Alissa Naqvi, Véronique Obry-Roguet, Marc-Antoine Valantin, Lise Cuzin, Eric Billaud, Antoine Cheret, David Rey, Christine Jacomet, Claudine Duvivier, Pascal Pugliese, Pierre Pradat, Laurent Cotte, Hepadat'AIDS Study Group
Published 2015-01-01

Higher rates of HBsAg clearance with tenofovir-containing therapy in HBV/HIV co-infection.

by Pierre Gantner, Laurent Cotte, Clotilde Allavena, Firouzé Bani-Sadr, Thomas Huleux, Claudine Duvivier, Marc-Antoine Valantin, Christine Jacomet, Véronique Joly, Antoine Chéret, Pascal Pugliese, Pierre Delobel, André Cabié, David Rey, Dat’AIDS Study Group
Published 2019-01-01

Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination

by Victor Virlogeux, Fabien Zoulim, Pascal Pugliese, Isabelle Poizot-Martin, Marc-Antoine Valantin, Lise Cuzin, Jacques Reynes, Eric Billaud, Thomas Huleux, Firouze Bani-Sadr, David Rey, Anne Frésard, Christine Jacomet, Claudine Duvivier, Antoine Cheret, Laurent Hustache-Mathieu, Bruno Hoen, André Cabié, Laurent Cotte, the Dat’AIDS Study Group
Published 2017-12-01

Antiretroviral exposure and comorbidities in an aging HIV-infected population: The challenge of geriatric patients.

by Clotilde Allavena, Matthieu Hanf, David Rey, Claudine Duvivier, Firouze BaniSadr, Isabelle Poizot-Martin, Christine Jacomet, Pascal Pugliese, Pierre Delobel, Christine Katlama, Véronique Joly, Christian Chidiac, Nathalie Dournon, Dominique Merrien, Thierry May, Jacques Reynes, Amandine Gagneux-Brunon, Catherine Chirouze, Thomas Huleux, André Cabié, François Raffi, Dat’AIDS study group
Published 2018-01-01